These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38956007)

  • 1. Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians.
    Tano M; Paubel P; Ribault M; Degrassat-Théas A
    Pharmacoecon Open; 2024 Jul; ():. PubMed ID: 38956007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France.
    Tano M; Paubel P; Ribault M; Degrassat-Théas A
    Appl Health Econ Health Policy; 2023 Sep; 21(5):799-811. PubMed ID: 37253898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Health Res Policy Syst; 2023 Jul; 21(1):68. PubMed ID: 37415219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
    Berreur B; Guerin F; Christophe B; Limido G; Paubel P
    Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 9. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
    Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
    Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
    Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
    J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland.
    Duggan B; Smith A; Barry M
    Int J Clin Pharm; 2021 Oct; 43(5):1251-1256. PubMed ID: 33560486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015-2021.
    Perelman J; Duarte-Ramos F; Melo Gouveia A; Pinheiro L; Ramos F; Vogler S; Mateus C
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):99-109. PubMed ID: 36356294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
    Cisek S; Choi D; Stubbings J; Bhat S
    Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
    Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
    Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.